Müeloom kliinilised uuringud osariigis Alabama
22 uuringut haiguse Müeloom jaoks otsivad osalejaid osariigis Alabama.
Linnad osariigis Alabama
Ametlik uuringutekst (inglise keeles)
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Alabama At Birmingham Hospital, Birmingham
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 28. sept 2026 · NCT04973605A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Alabama Oncology, Birmingham
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT07518186A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama Birmingham, Birmingham
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT04634552A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama at Birmingham Hospital, Birmingham
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 23. sept 2026 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
VärbamineFaas 2
Vanused 12 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT02693535A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- University of Alabama at Birmingham, Birmingham
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 15. sept 2026 · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 14. sept 2026 · NCT06297226A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Infirmary Health - Diagnostic & Medical Clinic (DMC), Mobile
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 9. sept 2026 · NCT06980480A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 2. sept 2026 · NCT06988488MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Infirmary Cancer Care, Mobile
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 24. aug 2026 · NCT06152575AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Birmingham
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 17. aug 2026 · NCT05850234A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Clearview Cancer Institute, Huntsville
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 6. aug 2026 · NCT07284758A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. juuli 2026 · NCT06121843Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
VärbamineFaas 2
Vanused 19 ja vanemad · Kõik sood · Uuendatud 4. juuni 2026 · NCT06974786A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Mobile
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. apr 2026 · NCT06679101A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 18. märts 2026 · NCT06153251Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
VärbamineFaas 1
Vanused 19 ja vanemad · Kõik sood · Uuendatud 13. veebr 2026 · NCT07333261Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
- University of Alabama at Birmingham, Birmingham
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 31. dets 2025 · NCT04991103Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
- Kirklin Clinic of UAB Hospital, Birmingham
Värbamine
Vanused 60 ja vanemad · Kõik sood · Uuendatud 24. dets 2025 · NCT05642884Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
- Kirklin Clinic of UAB Hospital, Birmingham
VärbamineVaatlusuuring
Vanused 50 ja vanemad · Kõik sood · Uuendatud 8. dets 2025 · NCT05556928CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2025 · NCT05722418A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- UAB Comprehensive Cancer Center, Birmingham
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 5. sept 2025 · NCT05372354Allikas ClinicalTrials.gov, andmed saadud 4. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.